Skip to main content
Erschienen in: Journal of Hepato-Biliary-Pancreatic Sciences 4/2013

01.04.2013 | Original article

Diagnostic and prognostic value of immunohistochemical expression of S100P and IMP3 in transpapillary biliary forceps biopsy samples of extrahepatic bile duct carcinoma

verfasst von: Hiroki Kawashima, Akihiro Itoh, Eizaburo Ohno, Ryoji Miyahara, Naoki Ohmiya, Tsutomu Tanaka, Yoshie Shimoyama, Shigeo Nakamura, Tomoki Ebata, Masato Nagino, Hidemi Goto, Yoshiki Hirooka

Erschienen in: Journal of Hepato-Biliary-Pancreatic Sciences | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Because the biopsy specimen of extrahepatic bile duct carcinoma (EHBDC) is small and shows reactive changes, the histological distinction between malignant and benign tissue can be difficult. Recent studies reported that S100P and insulin-like growth factor II mRNA-binding protein 3 (IMP3) were not only diagnostic molecules but also prognostic biomarkers in several organs. The objective of this study is to clarify the diagnostic and prognostic value of immunohistochemical expression of S100P and IMP3 in transpapillary biliary forceps biopsy (TBFB) samples.

Methods

The TBFB samples were collected from 80 patients (EHBDC, 68 patients; benign, 12 patients), retrospectively.

Results

When using cytoplasmic-positive staining for IMP3 as a marker of malignancy, the sensitivity and specificity reached 79.4 and 91.7 %, respectively. The sensitivity, specificity and accuracy achieved 89.7, 91.7 and 90.0 %, respectively, when using positive staining for IMP3 and/or positive histology as a maker of malignancy. While univariate (P = 0.033) and multivariate (P = 0.039) analysis revealed that S100P-positive EHBDC patients showed significantly shorter survival.

Conclusions

The results of this study suggest that immunohistochemical staining for IMP3 is useful in the diagnosis of EHBDC and that of S100P is useful as a prognostic marker for EHBDC.
Literatur
1.
Zurück zum Zitat Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nimura Y, et al. Hepatopancreatoduodenectomy for cholangiocarcinoma: a single-center review of 85 consecutive patients. Ann Surg. 2012;256:297–305.PubMedCrossRef Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, Nimura Y, et al. Hepatopancreatoduodenectomy for cholangiocarcinoma: a single-center review of 85 consecutive patients. Ann Surg. 2012;256:297–305.PubMedCrossRef
2.
Zurück zum Zitat Nagino M, Kamiya J, Nishio H, Ebata T, Arai T, Nimura Y. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer surgical outcome and long-term follow-up. Ann Surg. 2006;243:364–72.PubMedCrossRef Nagino M, Kamiya J, Nishio H, Ebata T, Arai T, Nimura Y. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer surgical outcome and long-term follow-up. Ann Surg. 2006;243:364–72.PubMedCrossRef
3.
Zurück zum Zitat Nagino M, Nimura Y, Nishio H, Ebata T, Igami T, Matsushita M, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma. Ann Surg. 2010;252:115–23.PubMedCrossRef Nagino M, Nimura Y, Nishio H, Ebata T, Igami T, Matsushita M, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma. Ann Surg. 2010;252:115–23.PubMedCrossRef
4.
Zurück zum Zitat Natsume S, Ebata T, Yokoyama Y, Igami T, Sugawara G, Shimoyama Y, et al. Clinical significance of left trisectionectomy for perihilar cholangiocarcinoma: an appraisal and complication with left hepatectomy. Ann Surg. 2012;255:754–62.PubMedCrossRef Natsume S, Ebata T, Yokoyama Y, Igami T, Sugawara G, Shimoyama Y, et al. Clinical significance of left trisectionectomy for perihilar cholangiocarcinoma: an appraisal and complication with left hepatectomy. Ann Surg. 2012;255:754–62.PubMedCrossRef
5.
Zurück zum Zitat Kawashima H, Itoh A, Ohno E, Goto H, Hirooka Y. Transpapillary biliary forceps biopsy to distinguish benign biliary stricture from malignancy: how many tissue samples should be obtained? Dig Endosc. 2012;24:s22–7.CrossRef Kawashima H, Itoh A, Ohno E, Goto H, Hirooka Y. Transpapillary biliary forceps biopsy to distinguish benign biliary stricture from malignancy: how many tissue samples should be obtained? Dig Endosc. 2012;24:s22–7.CrossRef
6.
Zurück zum Zitat Sugiyama M, Atomi T, Wada N, Kuroda A, Muto T. Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosis biliary strictures: a prospective comparative study with bile brush cytology. Am J Gastroenterol. 1996;91:465–7.PubMed Sugiyama M, Atomi T, Wada N, Kuroda A, Muto T. Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosis biliary strictures: a prospective comparative study with bile brush cytology. Am J Gastroenterol. 1996;91:465–7.PubMed
7.
Zurück zum Zitat Tamada K, Tomiyama T, Wada S, Ohashi A, Satoh Y, Ido K, et al. Endoscopic transpapillary bile duct biopsy with the combination of intraductal ultrasonography in the diagnosis of biliary strictures. Gut. 2002;50:326–31.PubMedCrossRef Tamada K, Tomiyama T, Wada S, Ohashi A, Satoh Y, Ido K, et al. Endoscopic transpapillary bile duct biopsy with the combination of intraductal ultrasonography in the diagnosis of biliary strictures. Gut. 2002;50:326–31.PubMedCrossRef
8.
Zurück zum Zitat De Bellis M, Sherman S, Fogel EL, Cramer H, Chappo J, McHenry L Jr, et al. Tissue sampling at ERCP in suspected malignant biliary strictures (Part 1). Gastrointest Endosc. 2002;56:552–61.PubMedCrossRef De Bellis M, Sherman S, Fogel EL, Cramer H, Chappo J, McHenry L Jr, et al. Tissue sampling at ERCP in suspected malignant biliary strictures (Part 1). Gastrointest Endosc. 2002;56:552–61.PubMedCrossRef
9.
Zurück zum Zitat De Bellis M, Sherman S, Fogel EL, Cramer H, Chappo J, McHenry L Jr, et al. Tissue sampling at ERCP in suspected malignant biliary strictures (Part 2). Gastrointest Endosc. 2002;56:720–30.PubMedCrossRef De Bellis M, Sherman S, Fogel EL, Cramer H, Chappo J, McHenry L Jr, et al. Tissue sampling at ERCP in suspected malignant biliary strictures (Part 2). Gastrointest Endosc. 2002;56:720–30.PubMedCrossRef
10.
Zurück zum Zitat Becker T, Gerke V, Kube E, Weber K. S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties. Eur J Biochem. 1992;207:541–7.PubMedCrossRef Becker T, Gerke V, Kube E, Weber K. S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties. Eur J Biochem. 1992;207:541–7.PubMedCrossRef
11.
Zurück zum Zitat Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999;19:1262–70.PubMed Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999;19:1262–70.PubMed
12.
Zurück zum Zitat Aishima S, Fujita N, Mano Y, Kubo Y, Tanaka Y, Taketomi A. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type. Am J Surg Pathol. 2011;35:590–8.PubMedCrossRef Aishima S, Fujita N, Mano Y, Kubo Y, Tanaka Y, Taketomi A. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type. Am J Surg Pathol. 2011;35:590–8.PubMedCrossRef
13.
Zurück zum Zitat Hamada S, Satoh K, Hirota M, Kanno A, Ishida K, Umino J, et al. Calcium-binding protein S100P is a novel diagnostic marker of cholangiocarcinoma. Cancer Sci. 2011;102:150–6.PubMedCrossRef Hamada S, Satoh K, Hirota M, Kanno A, Ishida K, Umino J, et al. Calcium-binding protein S100P is a novel diagnostic marker of cholangiocarcinoma. Cancer Sci. 2011;102:150–6.PubMedCrossRef
14.
Zurück zum Zitat Levy M, Lin F, Xu H, Dhall D, Spaulding BO, Wang HL. S100P, von Hipple-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Hum Pathol. 2010;41:1210–9.PubMedCrossRef Levy M, Lin F, Xu H, Dhall D, Spaulding BO, Wang HL. S100P, von Hipple-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Hum Pathol. 2010;41:1210–9.PubMedCrossRef
15.
Zurück zum Zitat Reiner MO, Frizsche FR, Clavien PA, Pestalozzi BC, Probst-Hensch N, Jochum W. IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. Hum Pathol. 2009;40:1377–87.CrossRef Reiner MO, Frizsche FR, Clavien PA, Pestalozzi BC, Probst-Hensch N, Jochum W. IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. Hum Pathol. 2009;40:1377–87.CrossRef
16.
Zurück zum Zitat Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, Hansen M, Eloranta JJ, Bhakta V, et al. Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol. 2005;166:81–92.PubMedCrossRef Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, Hansen M, Eloranta JJ, Bhakta V, et al. Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol. 2005;166:81–92.PubMedCrossRef
17.
Zurück zum Zitat Hashimoto K, Yamamoto H, Shiratsuchi H, Nakashima T, Tamiya S, Higaki Y, et al. S100P expression in ductal type of carcinoma ex pleomorphic adenoma. Am J Surg Pathol. 2011;35:346–55.PubMedCrossRef Hashimoto K, Yamamoto H, Shiratsuchi H, Nakashima T, Tamiya S, Higaki Y, et al. S100P expression in ductal type of carcinoma ex pleomorphic adenoma. Am J Surg Pathol. 2011;35:346–55.PubMedCrossRef
18.
Zurück zum Zitat Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K. Expression of a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol. 2007;20:242–7.PubMedCrossRef Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K. Expression of a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol. 2007;20:242–7.PubMedCrossRef
19.
Zurück zum Zitat Lin F, Shi J, Liu H, Hull ME, Dupree W, Prichard JW, et al. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis. Am J Surg Pathol. 2008;32:78–91.PubMedCrossRef Lin F, Shi J, Liu H, Hull ME, Dupree W, Prichard JW, et al. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis. Am J Surg Pathol. 2008;32:78–91.PubMedCrossRef
20.
Zurück zum Zitat Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H. IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol. 2008;21:431–7.PubMedCrossRef Pryor JG, Bourne PA, Yang Q, Spaulding BO, Scott GA, Xu H. IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol. 2008;21:431–7.PubMedCrossRef
21.
Zurück zum Zitat Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005;29:188–95.PubMedCrossRef Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005;29:188–95.PubMedCrossRef
22.
Zurück zum Zitat Kawashima H, Itoh A, Ohno E, Itoh Y, Ebata T, Nagino M, et al. Preoperative endoscopic nasobiliary drainage in 164 consecutive patients with suspected perihilar cholangiocarcinoma—a retrospective study of efficacy and risk factors related to complications. Ann Surg (in press). Kawashima H, Itoh A, Ohno E, Itoh Y, Ebata T, Nagino M, et al. Preoperative endoscopic nasobiliary drainage in 164 consecutive patients with suspected perihilar cholangiocarcinoma—a retrospective study of efficacy and risk factors related to complications. Ann Surg (in press).
23.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A 3rd. AJCC cancer staging manual. 7th ed. Berlin: Springer; 2010. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A 3rd. AJCC cancer staging manual. 7th ed. Berlin: Springer; 2010.
24.
Zurück zum Zitat Sakamoto E, Nimura Y, Hayakawa N, Kamiya J, Kondo S, Nagino M, et al. The pattern of infiltration at the proximal border of hilar bile duct carcinoma. A histologic analysis of 62 resected cases. Ann Surg. 1998;227:405–11.PubMedCrossRef Sakamoto E, Nimura Y, Hayakawa N, Kamiya J, Kondo S, Nagino M, et al. The pattern of infiltration at the proximal border of hilar bile duct carcinoma. A histologic analysis of 62 resected cases. Ann Surg. 1998;227:405–11.PubMedCrossRef
25.
Zurück zum Zitat Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Lyon: IARC; 2010. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Lyon: IARC; 2010.
26.
Zurück zum Zitat Takahashi Y, Nagino M, Nishio H, Ebata T, Igami T, Nimura Y. Percutaneous transhepatic biliary drainage catheter tract recurrence in cholangiocarcinoma. Br J Surg. 2010;97:1860–6.PubMedCrossRef Takahashi Y, Nagino M, Nishio H, Ebata T, Igami T, Nimura Y. Percutaneous transhepatic biliary drainage catheter tract recurrence in cholangiocarcinoma. Br J Surg. 2010;97:1860–6.PubMedCrossRef
Metadaten
Titel
Diagnostic and prognostic value of immunohistochemical expression of S100P and IMP3 in transpapillary biliary forceps biopsy samples of extrahepatic bile duct carcinoma
verfasst von
Hiroki Kawashima
Akihiro Itoh
Eizaburo Ohno
Ryoji Miyahara
Naoki Ohmiya
Tsutomu Tanaka
Yoshie Shimoyama
Shigeo Nakamura
Tomoki Ebata
Masato Nagino
Hidemi Goto
Yoshiki Hirooka
Publikationsdatum
01.04.2013
Verlag
Springer Japan
Erschienen in
Journal of Hepato-Biliary-Pancreatic Sciences / Ausgabe 4/2013
Print ISSN: 1868-6974
Elektronische ISSN: 1868-6982
DOI
https://doi.org/10.1007/s00534-012-0581-z

Weitere Artikel der Ausgabe 4/2013

Journal of Hepato-Biliary-Pancreatic Sciences 4/2013 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.